Lilly's Cyramza fails in another Phase III study
Eli Lilly's Cyramza (ramucirumab) has failed in the Phase III REACH trial in patients with hepatocellular carcinoma, casting further doubt on the therapeutic breadth of the anti-angiogenic agent.
Eli Lilly's Cyramza (ramucirumab) has failed in the Phase III REACH trial in patients with hepatocellular carcinoma, casting further doubt on the therapeutic breadth of the anti-angiogenic agent.